N1-Methyladenosine-Related lncRNAs Are Potential Biomarkers for Predicting Prognosis and Immune Response in Uterine Corpus Endometrial Carcinoma

Abstract

Uterine corpus endometrial carcinoma (UCEC) is a malignant disease that, at present, has no well-characterised prognostic biomarker. In this study, two clusters were identified based on 28 N1-methyladenosine- (m1A-) related long noncoding RNAs (lncRNAs), of which cluster 1 was related to immune pathways according to the results of an enrichment analysis. We further observed better prognosis in patients with higher levels of immune cell infiltration, tumor mutation burden, microsatellite instability, and immune checkpoint gene expression. In addition, through Cox regression analysis and least absolute shrinkage and selection operator regression analysis, 10 m1A-related lncRNAs (mRLs) were employed to build a prognosis model. We found that people in higher risk categories had a poorer survival probability than those in lower risk. Low-risk samples were enriched with immune-related pathways, while the high-risk group was similar to the definition of the “immune desert” phenotype, which was associated with decreased immune infiltration, T cell failure, and decreased tumor mutation burden, while also being insensitive to immunotherapy and chemotherapy. This mRL-based model has the ability to accurately predict the prognosis of UCEC patients, and the mRLs could become promising therapeutic targets in enhancing the response of immunotherapy.

Identification of immunogenic cell death‐associated subtypes and characterization of the tumor microenvironment in endometrial cancer

“…However, the reality is that owing to the heterogeneity of EC, traditional clinicopathological indicators are not sufficient to accurately predict survival outcomes 32 . With the rapid development of high‐throughput sequencing technology, our understanding of the pathogenesis and molecular genetic characteristics of endometrial cancer has been further enhanced, and individualized and precise treatment based on molecular genetic characteristics has revolutionized the treatment mode of endometrial cancer 33 . Therefore, the discovery of new biomarkers for the prognosis and treatment of EC has become an urgent clinical problem to be solved.…”

RNA N6-methyladenosine modification in female reproductive biology and pathophysiology

“…m 7 G modification is usually catalysed by METTL1 and located at the 5' caps and internal positions of eukaryotic mRNA [152]. Several studies on endometrial cancer have found that m 1 A-and m 7 G-related lncRNAs and miRNAs can be used to construct tumour-related prognostic models and are associated with different immune infiltration phenotypes and drug susceptibility in endometrial cancer [153][154][155][156]. Pseudouridine is the most abundant modified nucleotide in RNA [157].…”

Construction of a ferroptosis scoring system and identification of LINC01572 as a novel ferroptosis suppressor in lung adenocarcinoma

“…N6-methyladenosine (m6A) is the most abundant epigenetic modification in eukaryotic mRNA and non-coding RNA, and this chemical modification process is dynamic and reversible ( Ma et al, 2019 ; Liu et al, 2022b ). It is generally accepted that m6A modifications are regulated by three proteins, including “writers,” “erasers,” and “readers” ( He et al, 2019 ).…”